← Leaderboards
Esra Akbay
Ut Southwestern Medical Center
$1,582,280
Attributed
$2,666,699
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,666,699 · 2
By mechanism
R01$2,666,699 · 2
Top collaborators
- Anthony J Davis3 shared
- Ralf Kittler3 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- John B Macmillan$6,404,277
- Angelique Wright Whitehurst$6,833,234
- Chuo Chen$9,073,859
- Amit Sawant$6,007,350
- Kathryn Ann O'Donnell$3,665,073
Others in their field
Other Rising Stars on “Novel Therapeutics”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Angee Greer · Ppd Development Lp$82,531,927
- Suma Babu · Massachusetts General Hospital$26,348,733
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Cynthia M Visness · Rho Federal Systems Division, Inc.$13,531,908
Research focus
Novel TherapeuticsResistanceInhibitorNormal CellRadiationRadiation TherapyEfficacy EvaluationImmunotherapyMalignant NeoplasmsNon-Small-Cell Lung CarcinomaPathway InteractionsProteinsCytotoxicAntitumor EffectCellsDna RepairImmuneImmune ResponseChemotherapyIn VitroMouse ModelNatural ImmunityDna DamageResponse
Grant awards (5)
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$551,399
R01 · FY2025 · CA
Overcoming Therapy Resistance in SCLC$539,763
R01 · FY2025 · CA · contact PI
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$523,830
R01 · FY2024 · CA
Overcoming Therapy Resistance in SCLC$500,308
R01 · FY2024 · CA · contact PI
Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC$551,399
R01 · FY2023 · CA